Skip to main content
. 2020 Aug 20;21(9):3704–3712. doi: 10.1021/acs.biomac.0c00812

Scheme 1. TLR7/8a Delivery in a Subcutaneous Murine Tumor Model.

Scheme 1

(A) Peritumoral TLR7/8a NP delivery results in lower levels of circulating cytokines (brown circles), enhanced drainage to lymph nodes, and potent activation of the TLR7/8 receptors in antigen presenting cells (APCs) (purple cells) like DCs and macrophages. The altered cytokine profile and enhanced drainage of TLR7/8a to lymph nodes significantly slows tumor growth, extends survival, and results in less systemic toxicity. (B) Peritumoral free TLR7/8a delivery results in increased levels of many circulating cytokines, nonspecific diffusion throughout the body, and likely less APC activation in lymph nodes. This delivery route leads to greater systemic toxicity and weaker antitumor effects.